Is CODX or EVAX more profitable?

Evaxion A/S has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Evaxion A/S's return on equity of -61.43% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Co-Diagnostics -6,531.77% -210.99% -174.97% Evaxion A/S N/A -61.43% -34.23%

Does the media prefer CODX or EVAX?

In the previous week, Co-Diagnostics had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for Co-Diagnostics and 2 mentions for Evaxion A/S. Co-Diagnostics' average media sentiment score of 0.24 beat Evaxion A/S's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CODX or RNAZ?

Co-Diagnostics presently has a consensus target price of $67.50, indicating a potential upside of 5,926.79%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities analysts plainly believe Co-Diagnostics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CODX or RNAZ?

In the previous week, Co-Diagnostics had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 5 mentions for Co-Diagnostics and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.44 beat Co-Diagnostics' score of 0.24 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KYNB or CODX more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Co-Diagnostics' net margin of -6,531.77%. Kyntra Bio's return on equity of 0.00% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Co-Diagnostics -6,531.77% -210.99% -174.97%

Does the media favor KYNB or CODX?

In the previous week, Co-Diagnostics had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 5 mentions for Co-Diagnostics and 3 mentions for Kyntra Bio. Co-Diagnostics' average media sentiment score of 0.24 beat Kyntra Bio's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MDXH or CODX more profitable?

MDxHealth has a net margin of -33.46% compared to Co-Diagnostics' net margin of -6,531.77%. MDxHealth's return on equity of 0.00% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -24.25% Co-Diagnostics -6,531.77% -210.99% -174.97%

Does the media prefer MDXH or CODX?

In the previous week, Co-Diagnostics had 2 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Co-Diagnostics and 3 mentions for MDxHealth. Co-Diagnostics' average media sentiment score of 0.24 beat MDxHealth's score of -0.06 indicating that Co-Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Co-Diagnostics (CODX) Competitors

$1.12 +0.03 (+2.75%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.09%)

As of 10/9/2026 07:55 PM Eastern

Compare

CODX vs. EVAX, CNTX, RNAZ, KYNB, and MDXH

Should you buy Co-Diagnostics stock or one of its competitors? Co-Diagnostics's main competitors and comparable companies include Evaxion A/S (EVAX), Context Therapeutics (CNTX), TransCode Therapeutics (RNAZ), Kyntra Bio (KYNB), and MDxHealth (MDXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Co-Diagnostics compare to Evaxion A/S?

Co-Diagnostics (NASDAQ:CODX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Co-Diagnostics has a beta of 2.9, indicating that its stock price is 190% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Co-Diagnostics presently has a consensus price target of $67.50, suggesting a potential upside of 5,926.79%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 258.31%. Given Co-Diagnostics' higher possible upside, equities analysts plainly believe Co-Diagnostics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S has higher revenue and earnings than Co-Diagnostics. Evaxion A/S is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	12.61	-$46.90M	-$10.32	N/A
Evaxion A/S	$7.53M	3.68	-$7.71M	-$1.21	N/A

Evaxion A/S has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Evaxion A/S's return on equity of -61.43% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
Evaxion A/S	N/A	-61.43%	-34.23%

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Co-Diagnostics had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for Co-Diagnostics and 2 mentions for Evaxion A/S. Co-Diagnostics' average media sentiment score of 0.24 beat Evaxion A/S's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evaxion A/S beats Co-Diagnostics on 9 of the 17 factors compared between the two stocks.

How does Co-Diagnostics compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Context Therapeutics has higher earnings, but lower revenue than Co-Diagnostics. Context Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Co-Diagnostics	$620K	12.61	-$46.90M	-$10.32	N/A

Context Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market.

Context Therapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Context Therapeutics' return on equity of -82.06% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

In the previous week, Co-Diagnostics had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Co-Diagnostics and 1 mentions for Context Therapeutics. Co-Diagnostics' average media sentiment score of 0.24 beat Context Therapeutics' score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Context Therapeutics	Neutral
Co-Diagnostics	Neutral

Context Therapeutics presently has a consensus target price of $6.17, indicating a potential upside of 1,927.18%. Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 5,926.79%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Context Therapeutics and Co-Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to TransCode Therapeutics?

Co-Diagnostics (NASDAQ:CODX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Co-Diagnostics presently has a consensus target price of $67.50, indicating a potential upside of 5,926.79%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities analysts plainly believe Co-Diagnostics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.0% of Co-Diagnostics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Co-Diagnostics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

TransCode Therapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
TransCode Therapeutics	N/A	-875.35%	-37.46%

In the previous week, Co-Diagnostics had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 5 mentions for Co-Diagnostics and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.44 beat Co-Diagnostics' score of 0.24 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransCode Therapeutics has lower revenue, but higher earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	12.61	-$46.90M	-$10.32	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

Summary

Co-Diagnostics beats TransCode Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kyntra Bio has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market.

Kyntra Bio presently has a consensus price target of $37.25, indicating a potential upside of 509.66%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 5,926.79%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Co-Diagnostics had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 5 mentions for Co-Diagnostics and 3 mentions for Kyntra Bio. Co-Diagnostics' average media sentiment score of 0.24 beat Kyntra Bio's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has a net margin of 2,199.13% compared to Co-Diagnostics' net margin of -6,531.77%. Kyntra Bio's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Kyntra Bio has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	3.84	$183.45M	$45.30	0.13
Co-Diagnostics	$620K	12.61	-$46.90M	-$10.32	N/A

Summary

Kyntra Bio beats Co-Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Co-Diagnostics had 2 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Co-Diagnostics and 3 mentions for MDxHealth. Co-Diagnostics' average media sentiment score of 0.24 beat MDxHealth's score of -0.06 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MDxHealth has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.9, suggesting that its share price is 190% more volatile than the broader market.

MDxHealth has a net margin of -33.46% compared to Co-Diagnostics' net margin of -6,531.77%. MDxHealth's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

15.0% of Co-Diagnostics shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MDxHealth presently has a consensus target price of $2.17, suggesting a potential upside of 267.42%. Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 5,926.79%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

MDxHealth has higher revenue and earnings than Co-Diagnostics. MDxHealth is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$114.02M	0.26	-$33.52M	-$0.72	N/A
Co-Diagnostics	$620K	12.61	-$46.90M	-$10.32	N/A

Summary

Co-Diagnostics beats MDxHealth on 10 of the 17 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.61M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-0.11	13.42	274.15	26.16
Price / Sales	12.61	1,237.94	590.34	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.12	17.17	11.21	6.34
Net Income	-$46.90M	-$22.69M	$3.50B	$381.90M
7 Day Performance	3.70%	-1.33%	-0.90%	-1.41%
1 Month Performance	1.82%	-8.44%	-4.44%	-3.48%
1 Year Performance	-90.15%	14.02%	6.96%	1.16%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	2.5065 of 5 stars	$1.12 +2.8%	$67.50 +5,926.8%	-91.3%	$7.61M	$620K	N/A	115	News Coverage Gap Down
EVAX Evaxion A/S	2.3177 of 5 stars	$3.27 +0.9%	$11.00 +236.4%	-52.3%	$29.50M	$7.53M	N/A	46	Analyst Forecast
CNTX Context Therapeutics	2.6561 of 5 stars	$0.32 -2.2%	$6.17 +1,833.1%	-78.3%	$29.31M	N/A	N/A	15
RNAZ TransCode Therapeutics	1.1068 of 5 stars	$1.63 -4.7%	N/A	-87.4%	$27.60M	N/A	N/A	12	Gap Up
KYNB Kyntra Bio	3.2138 of 5 stars	$6.79 -1.6%	$37.25 +448.6%	N/A	$27.50M	$6.44M	0.15	570	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. EVAX, CNTX, RNAZ, KYNB, and MDXH

How does Co-Diagnostics compare to Evaxion A/S?

Summary

How does Co-Diagnostics compare to Context Therapeutics?

Summary

How does Co-Diagnostics compare to TransCode Therapeutics?

Summary

How does Co-Diagnostics compare to Kyntra Bio?

Summary

How does Co-Diagnostics compare to MDxHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. EVAX, CNTX, RNAZ, KYNB, and MDXH

How does Co-Diagnostics compare to Evaxion A/S?

Which has more volatility and risk, CODX or EVAX?

Do analysts prefer CODX or EVAX?

Which has preferable earnings & valuation, CODX or EVAX?

Is CODX or EVAX more profitable?

Do insiders & institutionals believe in CODX or EVAX?

Does the media prefer CODX or EVAX?

Summary

How does Co-Diagnostics compare to Context Therapeutics?

Do insiders & institutionals believe in CNTX or CODX?

Which has preferable earnings and valuation, CNTX or CODX?

Which has more volatility & risk, CNTX or CODX?

Is CNTX or CODX more profitable?

Does the media favor CNTX or CODX?

Do analysts recommend CNTX or CODX?

Summary

How does Co-Diagnostics compare to TransCode Therapeutics?

Do analysts prefer CODX or RNAZ?

Do institutionals and insiders believe in CODX or RNAZ?

Which has more volatility & risk, CODX or RNAZ?

Is CODX or RNAZ more profitable?

Does the media refer more to CODX or RNAZ?

Which has higher earnings & valuation, CODX or RNAZ?

Summary

How does Co-Diagnostics compare to Kyntra Bio?

Do insiders and institutionals have more ownership in KYNB or CODX?

Which has more volatility and risk, KYNB or CODX?

Do analysts recommend KYNB or CODX?

Does the media favor KYNB or CODX?

Is KYNB or CODX more profitable?

Which has higher earnings and valuation, KYNB or CODX?

Summary

How does Co-Diagnostics compare to MDxHealth?

Does the media prefer MDXH or CODX?

Which has more risk & volatility, MDXH or CODX?

Is MDXH or CODX more profitable?

Do insiders and institutionals hold more shares of MDXH or CODX?

Do analysts recommend MDXH or CODX?

Which has stronger earnings and valuation, MDXH or CODX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools